Protocols›Hormonal & longevity›Hormonal Optimisation — TRT
← Protocols
Has approved analogues · off-label hereUS-clinic · off-labelNo approved clinical use

Hormonal Optimisation — TRT

Stack: Gonadorelin + BPC-157 + Ipamorelin + NAD⁺ / NMN · full trt-centred
"A full TRT protocol with a peptide support layer. TRT is one of the best-evidenced hormonal therapies there is — the peptides bolted around it are not."
GoalFull TRT-centred
Compounds4 · Gonadorelin + BPC-157 + Ipamorelin + NAD⁺ / NMN
Humans exposed (est.)Very high (TRT)
StatusMHRA (UK): Testosterone & Gonadorelin are prescription-only medicines · FDA (US): TRT licensed; peptide layer not approved
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Has approved analogues
Where / who
Community / athlete and clinic use as tagged above.
Use status
TRT is standard licensed therapy worldwide.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
BPC-157 / Ipamorelin: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing; removed from Category 2 Apr 2026, 503A Bulks List decision pending the PCAC meeting 23–24 Jul 2026.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. Strong for TRT; community-tier for the peptides.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Why this combination

Testosterone replacement (POM, not sold here) is strongly evidenced and clinician-managed. Gonadorelin supports the axis. The peptide layer is community-tier convention. The honest split is the same as the companion protocol: the TRT is the medicine.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake Very high

TRT is standard licensed therapy worldwide.

Human efficacy Mixed

Strong for TRT; community-tier for the peptides.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

Best-evidenced part is the prescription; the rest is support.

Fast facts
Compounds

Gonadorelin · BPC-157 · Ipamorelin · NAD⁺ / NMN

Humans exposed (est.)

Very high (TRT).

UK strip

AMBER — POM in stack